ILC2s Induce Adaptive Th2-Type Immunity in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Jiang, Min; Liu, Huifang; Zheng, Li; Wang, Jing; Zhang, Fengbo; Cao, Kaixiu; Li, Fengsen; Ding, Jianbing

doi:10.1155/2019/3140183

Cited by 32 publications

(45 citation statements)

References 50 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were higher levels of IL-4, IL-6, and IL-8 in serum or sputum from AECOPD than those from the control subjects. 25 However, IL-4 and IL-8 cannot judge the different type of AECOPD as biomarkers. Higher levels of sputum and serum IL-6 were observed in eosinophilic AECOPD than those in neutrophilic AECOPD.…”

Section: Discussionmentioning

confidence: 99%

“…Th2 cells and ILC2 cells then produce IL-5 and IL-13. 25,27 IL-5 plays a central role in stimulating the growth, differentiation, and maturation of eosinophils in the bone marrow and also is implicated in the function and survival of eosinophils. 28 Clinical trials have shown that mepolizumab, which is a monoclonal antibody against IL-5, can reduce the exacerbation rate of COPD by inhibiting blood eosinophilia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients

Gao

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory disease and eosinophils (EOS) participate in inflammation process. Acute exacerbation of COPD (AECOPD) is an inevitable trend in the development of the disease and has attracted widespread attention. In the present study, 108 hospitalized patients with AECOPD were collected and the levels of interleukin-13 and eosinophil cationic protein in the serum and sputum were measured to explore their clinical value in eosinophilic AECOPD patients. The patients were divided into an eosinophilic group (52 cases, 48.15%) and a noneosinophilic group (56 cases, 51.85%). The eosinophilic group had fewer acute exacerbations in the past year, shorter average hospitalization days, lower respiratory failure rate, mechanical ventilation utilization rate, and lower CAT and mMRC scores ( P < 0.05). The levels of interleukin-13 and eosinophil cationic protein in sputum in the eosinophilic group were higher than those in the noneosinophilic group ( P < 0.05), and there was no significant difference in the serum between the two groups ( P > 0.05). The receiver operating characteristic (ROC) curves of sputum interleukin-13 and eosinophil cationic protein predicting peripheral blood EOS% ≥2% of AECOPD patients were statistically significant ( P < 0.05). The noneosinophilic group had a higher rate of rehospitalization due to acute exacerbation during the one-year follow-up, and there was no significant difference in mortality between the two groups. The results show that eosinophils in peripheral blood are a simple, convenient, and inexpensive index for assessing the condition and prognosis of AECOPD patients. Interleukin-13 and eosinophil cationic protein are involved in the pathogenesis of eosinophilic AECOPD and may be the new targeted anti-inflammatory therapies in the future. Impact statement Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an inevitable trend in the development of the disease and eosinophils (EOS) participate in inflammation process. It is important to explore some relatively simple biomarkers in AECOPD which are useful to recognize the disease. In the present study, 108 hospitalized patients with AECOPD were collected and the levels of IL-13 and ECP in the serum and sputum were measured. The levels of IL-13 and ECP in sputum in the eosinophilic group were higher than those in the noneosinophilic group. Moreover, the noneosinophilic group had a higher rate of rehospitalization due to acute exacerbation during the one-year follow-up. The results show that eosinophils in peripheral blood are a simple, convenient, and inexpensive index for assessing the condition and prognosis of AECOPD patients. IL-13 and ECP are involved in the pathogenesis of eosinophilic AECOPD and may be the new targeted anti-inflammatory therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients

Gao

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…It is involved in regulation of inflammatory and immune responses as well as mucous hypersecretion [ 125 , 126 ]. Eosinophils have shown secretion of IL-13 under GM-CSF and/or IL-5 stimulation [ 127 ] and ILC2 cells are also able to secrete IL-5 and IL-13 under stimulation of IL-33 and IL-25 [ 128 ]. ILC2s have been found increased in patients with stable COPD or during acute exacerbation [ 46 ].…”

Section: Pathophysiology and Molecular Mechanismsmentioning

confidence: 99%

Targeted therapy in eosinophilic chronic obstructive pulmonary disease

et al. 2021

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over the last decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8+ T-cells. Asthma is a heterogeneous chronic inflammatory airway disease. The most studied subtypes is T2 high eosinophilic asthma, for which there are an increasing number of biologic agents developed. However, both asthma and COPD are complex and share common pathophysiologic mechanisms. They are known as overlapping syndromes as approximately 40% of patients with COPD present an eosinophilic airway inflammation. Several studies suggest a putative role of eosinophilia in lung function decline and COPD exacerbation. Recently, pharmacological agents targeting eosinophilic traits in uncontrolled eosinophilic asthma, especially monoclonal antibodies directed against interleukins (IL5, IL4, IL13) or their receptors, have shown promising results. This review examines data on the rationale for such biological agents and assesses efficacy in T2-endotype COPD patients.

show abstract

“…However, only ILC2s in humans express PD‐1 but not ILC1s and ILC3s 252 . The lungs of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients also show the ILC2‐mediated Th2 immune response induction 253 . These patients also show the increase in systemic IL‐4 levels and the number of ILC2s in peripheral blood.…”

Section: Ilc and T Cell Cross‐talk During Allergic Asthma And Other Cmentioning

confidence: 99%

“…These patients also show the increase in systemic IL‐4 levels and the number of ILC2s in peripheral blood. These ILC2s also overexpress MHC‐II and CD80 as compared to the control group, and serve as APCs to stimulate CD4 + T cell immune response in AECOPD 253 …”

Section: Ilc and T Cell Cross‐talk During Allergic Asthma And Other Cmentioning

confidence: 99%

Innate lymphoid cell and adaptive immune cell cross-talk: A talk meant not to forget

Kumar

2020

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Innate lymphoid cells (ILCs) are a relatively new class of innate immune cells with phenotypical characters of lymphocytes but genotypically or functionally behave as typical innate immune cells. They have been classically divided into 3 groups (group 1 ILCs or ILC1s, group 2 ILCs or ILC2s, and group 3 ILCs or ILC3s). They serve as the first line of defense against invading pathogens and allergens at mucosal surfaces. The adaptive immune response works effectively in association with innate immunity as innate immune cells serve as APCs to directly stimulate the adaptive immune cells (various sets of T and B cells). Additionally, innate immune cells also secrete various effector molecules, including cytokines or chemokines impacting the function, differentiation, proliferation, and reprogramming among adaptive immune cells to maintain immune homeostasis. Only superantigens do not require their processing by innate immune cells as they are recognized directly by T cells and B cells. Thus, a major emphasis of the current article is to describe the cross‐talk between different ILCs and adaptive immune cells during different conditions varying from normal physiological situations to different infectious diseases to allergic asthma.

show abstract

ILC2s Induce Adaptive Th2-Type Immunity in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Cited by 32 publications

References 50 publications

Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients

Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients

Targeted therapy in eosinophilic chronic obstructive pulmonary disease

Innate lymphoid cell and adaptive immune cell cross-talk: A talk meant not to forget

Contact Info

Product

Resources

About